Piper Sandler Maintains Neutral on Staar Surgical, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained a Neutral rating on Staar Surgical (STAA) but lowered the price target from $40 to $33.
February 27, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler maintains a Neutral rating on Staar Surgical but lowers the price target from $40 to $33.
The reduction in price target by Piper Sandler from $40 to $33, while maintaining a Neutral stance, suggests a downward revision in the expected performance or valuation of Staar Surgical. This could lead to a negative short-term impact on the stock price as investors adjust their expectations based on the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100